On the stock market since 2019, it operates in the world of health and science. It has 4 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 27% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 20% a year on average.
Sales run at $3.0M a year. A small number, but proof the product has real buyers.
There is $7.9M in the vault; even if every debt were paid off, $7.9M would remain.
A loss of $2.7M against $3.0M in annual sales.
This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, XBIOW sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: XBIOW is a high-risk stock — not yet profitable, and its future rides on its product catching on.